... disease, in which the cancer has spread beyond the breast, the researchers say.
Further, the drug Herceptin, which is used to treat HER2-positive breast cancer, was found to target and destroy the ...
... an excess amount of the HER2 protein on their surface, which makes the cancer more aggressive. Herceptin, also known as trastuzumab, is a monoclonal antibody that latches on to these proteins and ...
... at The University of Texas M. D. Anderson Cancer Centre have discovered that when treated with herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of ...
Researchers have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. However, of those ...
(PhysOrg.com) -- Breast cancer drug Herceptin can extend the lives of patients with incurable stomach cancer by nearly three months, according to an international study involving researchers from the ...
... or laboratory analysis.
"This paper is a major step forward because as revolutionary as Herceptin has been, there are many patients who fail. This helps us understand why and it would not have been ...
Cancer researchers are turning to mathematical models to help answer important clinical questions, and a new article illustrates how the technique may answer questions about Herceptin resistance.
(PhysOrg.com) -- A study involving a University of Glasgow cancer specialist has found that using Herceptin increases survival rates among those with stomach cancer.
Drug trial involving 1,000 women given Herceptin shows drug is not effective as thought
... There are several ¡¥designer' cancer drugs that fight tumors driven by EGFR-like receptors, such as Herceptin, Erbitux and Tarceva," says lead author Mark A. Lemmon, PhD, Professor of Biochemistry and ...
... to decide if patients should receive specific treatments such as hormonal inhibitors and/or the drug Herceptin. He predicts that drugs to treat the mutations found in melanomas could be developed in ...
... modulated radiation therapy to treat prostate cancer; $50,000 per patient per year for trastuzumab (Herceptin) in the treatment of HER-2–positive breast cancer; $1,800 per month for gefitinib (Iressa) ...
WASHINGTON, July 8 (UPI) -- The U.S. Food and Drug Administration said it's approved a genetic test for determining if breast cancer patients should be treated with the drug Herceptin.
... Gab2, operates downstream of a major breast cancer oncogene, HER2, the target of the drug Herceptin.
A research team from the Garvan Institute of Medical Research, led by Professor Roger Daly, has ...
... four -- have poorer prognoses and clinical outcomes than those who don't. The drugs Herceptin and Lapatinib, prescribed in combination with other chemotherapeutic agents, have improved this picture ...
